An updated Review on Therapeutic Potential of Entrectinib as a Promising TrK, ROS 1, and ALK Inhibitor in Solid Tumors and Lung Cancer
M. Archana, Mariya Palathingal, K. Athulya Damodharan, P. Ashisha & Nuaman, Akash Marathakam · Journal of Pharmaceutical Research International · 2021
Entrectinib is a selective inhibitor of tyrosine kinases , tropomyosin receptor kinases that targets oncogenic rearrangements in Neurotropic Tyrosine Receptor kinase, c-ros oncogene 1 and Anaplastic lymphoma kinase used for the treatment of various solid tumors. Entrectinib gaine...
Open access
Research Article
10.9734/jpri/2021/v33i44A32633